ArticleOncogene2026
KDM4A drives TGCT metastasis by inducing focal adhesion disassembly via STAT1-mediated CCL3 transcriptional activation.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dysregulation of histone demethylation is a pivotal epigenetic event driving malignant tumor progression. Thus, it is critical to understand the downstream signaling pathways that govern dysregulation of histone demethylation. Here, we identified KDM4A as the exclusively and significantly up-regulated member in testicular germ cell tumors (TGCTs) through a pan-family expression screen of histone demethylases (KDM1-8 and JMJD6) using the GEPIA database. KDM4A knockdown markedly inhibits TGCT cell migration and invasion in vitro, and metastatic potential in vivo. Mechanistically, KDM4A induces H3K9me3 demethylation at the CCL3 promoter, thereby restoring chromatin accessibility to facilitate STAT1-dependent CCL3 transcriptional activation, which activates the PI3K/AKT pathway, ultimately promoting focal adhesion turnover and enhancing cellular invasiveness. Furthermore, in a lung metastasis model, KDM4A significantly promoted distal colonization of TGCT in a CCL3-dependent manner. Summary, our findings reveal that KDM4A is a critical epigenetic regulator of TGCT metastasis, driving tumor progression via the STAT1-dependent CCL3 transcriptional activation, which promotes focal adhesion turnover by PI3K/AKT axis. Hence, targeting KDM4A may be a promising therapeutic strategy for improving the clinical prognosis of patients with metastatic TGCT.
Identifiers
42829378What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.